EGFR and non-small cell lung carcinoma: Erlotinib received approval as a first-line treatment for patients with EGFR mutation in 2011 EURTAC [40] and OPTIMAL trials [41,42] proved the superiority in terms of PFS of erlotinib over first-line platinum-based chemotherapy in NSCLC patients harboring EGFR mutation (13.1 versus 4.6 months; HR 0.16 [95% CI 0.10–0.26]; p < 0.0001).